GRANDPHARMA's conjugate drug TLX591-CDx has reached its primary clinical endpoint
GRANDPHARMA (00512.HK) announced that the innovative radiolabeled drug TLX591-CDx for diagnosing prostate cancer has recently achieved positive top-line results in a Phase III clinical trial conducted in China, successfully reaching the primary clinical endpoint. In addition, the RDC product TLX591 for the treatment of prostate cancer has been approved in China to join an international multicenter Phase III clinical study.
In the future, the combination of these two products is expected to provide more precise and efficient diagnostic and therapeutic solutions for prostate cancer patients in China
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments